LIFE SAVING DRUGS PROGRAM EXPERT PANEL

FIFTH MEETING: 16-17 April 2020

**AGENDA**

1. **Standing business**

* Welcome & apologies
* Declaration of potential or actual Conflict of Interest
* Correspondence
* Update from Secretariat

1. **Reviews of existing LSDP medicines**

TRANCHE 1

* Consideration of Fabry disease medicines final report
* Consideration of Gaucher disease medicines draft report

TRANCHE 2 – consideration of draft reports

* Idursulfase (Elaprase®) for treatment of Mucopolysaccharidosis type II
* Alglucosidase alfa (Myozyme®) for treatment of Pompe disease
* Eculizumab (Soliris®) for treatment of Paroxysmal Nocturnal Haemoglobinuria

TRANCHE 3 – updates

* Laronidase (Aldurazyme®) for treatment of Mucopolysaccharidosis type I
* Galsulfase (Naglazyme®) for treatment of Mucopolysaccharidosis type VI
* Nitisinone (Orfadin®) for Hereditary Tyrosinaemia type I

1. **Applications for new LSDP medicines**
2. **Other business**